Scientific Program

IMPORTANT NOTE: Virtual meeting time indicated in the scientific program is expressed as GMT Time Zone. Please check time as per your timezone

21.05.2021
22.05.2021
21.05.2021
08:15 - 08:20
Hall C

3rd Istanbul Immunohematology Summit

Opening Remarks Güner Hayri Özsan (08:00 - 08:15)
Opening Remarks Muhlis Cem Ar (08:00 - 08:15)
21.05.2021
08:20 - 08:30

Break

21.05.2021
08:30 - 09:45
Hall C

COVID-19 and Immunity

*Scientific Chair : Feyzi İlhan Tezcan
Immunological Basis COVID- 19 Infection and Immunoreactivity Gülderen Demirel (08:30 - 09:45)
From Exosome Cancer Immunotherapy to COVID-19 Specıfıc VLP Vaccine Development İhsan Gürsel (Turkey) (08:30 - 09:45)
21.05.2021
09:45 - 10:00

Break

21.05.2021
10:00 - 11:15
Hall C

Off the Shelf Cellular Therapies

*Scientific Chair : Günhan Gürman
CAR-T Cells Hermann Einsele (10:00 - 11:15)
NK Cells Tolga Sütlü (Turkey) (10:00 - 11:15)
21.05.2021
11:15 - 11:30

Break

21.05.2021
11:30 - 12:45
Hall C

Monoclonal Antibody Directed Immunotherapies

*Scientific Chair : Meral Beksaç
Beyond Naked Antibodies Mark Cragg (11:30 - 12:45)
Check Point Inhibitors Fuat Hulusi Demirelli (11:30 - 12:45)
21.05.2021
13:40 - 13:45
Hall A

Opening Ceremony

Güner Hayri Özsan (13:30 - 13:45)
Muhlis Cem Ar (13:30 - 13:45)
Şule Ünal Cangül (13:30 - 13:45)
Meltem Kurt Yüksel (13:30 - 13:45)
Reyhan Küçükkaya (13:30 - 13:45)
Neslihan Andıç (13:30 - 13:45)
Leylagül Kaynar (13:30 - 13:45)
21.05.2021
13:45 - 14:00

Break

21.05.2021
14:00 - 15:30
Hall A

Multiple Myeloma

*Scientific Chair : Ömür Gökmen Sevindik , Pieter Sonneveld
Antibodies Upfront or at Relapse? Pieter Sonneveld (14:00 - 15:30)
What is the Best Treatment Sequence for RRMM? Thierry Facon (14:00 - 15:30)
Is MRD the New Outcome in Clinical Practice? Francesca Gay (14:00 - 15:30)
Hall B

Pediatric Leukemias-I

*Scientific Chair : Hale Ören , Michael Dworzak
Advancements of the I-BFM FLOW Network: Innovative Solutions for Diagnosis and MRD Assessment in Acute Leukemias Michael Dworzak (14:00 - 15:30)
FLOW-MRD in the Era of BITE & CART Therapies Alexander Popov (14:00 - 15:30)
Towards shaping a high-quality network of FLOW-MRD labs in Turkey Günnur Deniz (14:00 - 15:30)
21.05.2021
15:30 - 16:00

Break

21.05.2021
16:00 - 16:45
Hall A

Janssen Satellite Symposium

*Scientific Chair : Meral Beksaç
New Dimension in Efficacy: Darzalex in RRMM Erdal Kurtoğlu (16:00 - 16:45)
New Dimension in Efficacy: Darzalex in RRMM Ömür Gökmen Sevindik (16:00 - 16:45)
21.05.2021
16:45 - 17:15

Break

21.05.2021
17:15 - 18:45
Hall A

Chronic Myeloid Leukemia

*Scientific Chair : Ahmet Emre Eşkazan , Susanne Saussele
Modern CML Treatment According to the New ELN Recommendations Mario Tiribelli (17:15 - 18:45)
Treatment Free Remission. A Goal for All CML Patients? Susanne Saussele (17:15 - 18:45)
New Options for Patients After 1st Line Ahmet Emre Eşkazan (17:15 - 18:45)
Hall B

Pediatric Leukemias-II

*Scientific Chair : Volkan Hazar , Mehmet Fatih Okçu
Epidemiology of Late Effects in Children with Acute Lymphoblastic Leukemia Mehmet Fatih Okçu (17:15 - 18:45)
Obesity and Metabolic Syndrome in Childhood Acute Lymphoblastic Leukemia Survivors Kala Kamdar (17:15 - 18:45)
Early Aging, Chronic Conditions and Biological Indicators of Aging in Childhood Acute Lymphoblastic Leukemia Survivors Monica Gramatges (17:15 - 18:45)
21.05.2021
18:45 - 19:15

Break

21.05.2021
19:15 - 20:45
Hall A

Indolent Lymphomas

*Scientific Chair : Meltem Olga Akay , Eva Kimby
Follicular Lymphoma with Focus on Therapy Eva Kimby (19:15 - 20:45)
Cellular Therapies for Follicular Lymphoma Koen Van Besien (19:15 - 20:45)
Management of Marginal Zone Lymphoma Catherine Thieblemont (19:15 - 20:45)
21.05.2021
20:45 - 21:00

Break

21.05.2021
21:00 - 21:45
Hall A

Amgen Satellite Symposium

*Scientific Chair : Ayşe Tülin Fıratlı Tuğlular
Carfilzomib Treatment in Relapsed/Refractory Multiple Myeloma Joseph Mikhael (21:00 - 21:45)
21.05.2021
21:45 - 22:00

Break

21.05.2021
22:00 - 23:00
Hall-1

MULTIPLE MYELOMA

*Scientific Chair : Fahir Özkalemkaş , Mutlu Arat
FREE LIGHT CHAIN ESCAPE IN MULTIPLE MYELOMA: IS IT AN EARLY CLUE OF AGGRESSIVE PROGRESSION? Boran Yavuz (22:00 - 23:00)
COMPARISON OF CANCER AND AGING RESEARCH GROUP SCORE (CARG) AND COMORBIDITY INDEX SCORES IN MULTIPLE MYELOMA PATIENTS Mehmet Baysal (22:00 - 23:00)
POSTINDUCTION FDG-PET IMAGING IMPROVES THE IMPACT OF BIOCHEMICAL RESPONSE ASSESSMENT ON TRANSPLANT OUTCOME Güldane Cengiz Seval (22:00 - 23:00)
PATIENT RELATED FACTORS OVERRIDE LENALIDOMIDE MAINTENANCE AS A FACTOR OF SEVERITY FOR COVID-19 INFECTION Ekin Kırcalı (22:00 - 23:00)
PACE-LIKE REGIMENS IN THE TREATMENT OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA Aylin Fatma Karataş (22:00 - 23:00)
THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION Atilla Uslu (22:00 - 23:00)
Hall-2

PRECLINIC/GENETIC

*Scientific Chair : Muhlis Cem Ar , Alphan Küpesiz
MYD88 EXPRESSION IN PRIMARY AND SECONDARY CNS LYMPHOMAS Berrin Balık Aydın (22:00 - 23:00)
PHENOTYPES OF BONE MARROW MONOCYTES IN STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: A DESCRIPTIVE PILOT STUDY Ekin Kırcalı (22:00 - 23:00)
THE IGLV3-21 LIGHT CHAIN ANALYSIS IN IR-RELATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS Nadiia Bilous (22:00 - 23:00)
KILLER IMMUNOGLOBULIN LIKE HAPLOTYPE BB IS OBSERVED MORE FREQUENTLY AMONG MYELOMA CASES COMPARED TO HEALTHY CONTROLS Yalım Akın (22:00 - 23:00)
MUTATION PROFILE OF THE PATIENTS TESTED WITH NEXT GENERATION SEQUENCING AND CLINICAL IMPLICATIONS Yaşa Gül Mutlu (22:00 - 23:00)
Hall-3

INFECTION/QUALITY OF LIFE

*Scientific Chair : Adalet Meral Güneş , Mustafa Nuri Yenerel (Turkey)
DETERMINATION OF INFECTION FREQUENCY IN PATIENTS USING RUXOLITINIB DUE TO GRAFT VERSUS HOST DISEASE Hülya Yılmaz (22:00 - 23:00)
EFFICACY OF ANTI-IL-6 ANTIBODY IN THREE PATIENTS WITH COVID-19 INFECTION AND MULTIPLE MYELOMA Anıca Dıvac (22:00 - 23:00)
ASSESSMENT OF POSSIBLE RISK FACTORS FOR THE DEVELOPMENT OF CORONAVIRUS INFECTION IN PATIENTS WITH HEMATOLOGICAL CANCERS Inna Kamaeva (22:00 - 23:00)
OUR CENTER EXPERIENCE OF MULTIPLE MYELOMA PATIENTS WITH COVID-19 Mehmet Sezgin Pepeler (22:00 - 23:00)
EVALUATION OF POSSIBLE EFFECTS OF THE COVID-19 PANDEMIC ON FEBRILE NEUTROPENIA EPISODES IN CHILDREN WITH ACUTE LEUKEMIA Şebnem Yılmaz (22:00 - 23:00)
QUALITY OF LIFE MEASURES OF THE PATIENTS WHO ARE DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES AND TIME EFFECT ON PARAMETERS Berrin Balık Aydın (22:00 - 23:00)
Hall-4

LEUKEMIA/LYMPHOMA

*Scientific Chair : Düzgün Özatlı , Şebnem Yılmaz
EVALUATION OF CLINICAL AND LABORATORY FINDINGS AT DIAGNOSIS AND RELAPSE IN CHILDREN WITH ACUTE LEUKEMIA Şebnem Yılmaz (22:00 - 23:00)
PERSISTENT POLYCLONAL B-CELL LYMPHOCYTOSIS WITH BINUCLEATED LYMPHOCYTES (PPBL) Berrin Balık Aydın (22:00 - 23:00)
ANALYSIS OF FACTORS PREDICTING EFFICACY OF IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS Mesut Tığlıoğlu (22:00 - 23:00)
DIAGNOSTIC CHALLENGES AND CONSEQUENT THERAPEUTIC DILEMMAS ENCOUNTERED IN CLASSIFYING ACUTE MYELOID LEUKEMIAS Mürüvvet Seda Aydın (22:00 - 23:00)
CLINICAL OUTCOMES AND TREATMENT PATTERNS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA:MULTICENTER RETROSPECTIVE ANALYSIS Serkan Güven (22:00 - 23:00)
GIANT MASS IN THE EYELID: T CELL LYMPHOMA Ferda Can (22:00 - 23:00)
Hall-5

LYMPHOMA

*Scientific Chair : Şule Mine Öztürk , Ebru Koca
IS SURGICAL EXCISIONAL BIOPSY STILL THE GOLD STANDARD DIAGNOSTIC APPROACH IN LYMPHOMAS? Yaşa Gül Mutlu (22:00 - 23:00)
BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTO-SCT IN HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER RETROSPECTIVE STUDY Meltem Olga Akay (22:00 - 23:00)
EVALUATION OF PD-1/ PD-L1 EXPRESSION, TUMOR MICROENVIRONMENT AND PROGNOSTIC FACTORS IN DIFFUSE LARGE B CELL LYMPHOMA Guldidar Basmacı (22:00 - 23:00)
BROWN ADIPOSE TISSUE FORMATION DUE TO NIVOLUMAB TREATMENT Elçin Erdoğan Yücel (22:00 - 23:00)
PRIMARY GASTRIC NK/T CELL LYMPHOMA WITH T CELL PHENOTYPE: A RARE EBV RELATED LOCALLY INVOLVED AGRESSIVE LYMPHOMA CASE. Derya Koyun (22:00 - 23:00)
THE EFFECT OF THE CELL OF ORIGIN USING HANS ALGORITHM ON PROGNOSIS IN DIFFUSE LARGE B CELL LYMPHOMAS Taha Kars (22:00 - 23:00)
22.05.2021
09:30 - 11:00
Hall A

Acute Myeloid Leukemia

*Scientific Chair : İnci Alacacıoğlu , Hartmut Döhner
Molecular Heterogeneity and Clonal Evolution of AML Lars Bullinger (09:30 - 11:00)
Combining New Agents with “3+7“ Chemotherapy in Fit Patients Hartmut Döhner (09:30 - 11:00)
New Agents For The Treatment of Older Patients Andrew Wei (09:30 - 11:00)
22.05.2021
11:00 - 11:30

Break

22.05.2021
11:30 - 13:00
Hall A

Chronic Lymphocytic Leukemia

*Scientific Chair : Fatih Demirkan , Michael Hallek
State-of-the Art First Line Therapy of CLL Michael Hallek (11:30 - 13:00)
Management of Relapsed CLL and Richter Transformation Davide Rossi (11:30 - 13:00)
Modelling of Response Pattern and Cloned Evolution of CLL Othman Al - Sawaf (11:30 - 13:00)
22.05.2021
13:00 - 13:30

Break

22.05.2021
13:30 - 14:15
Hall A

Abbvie Satellite Symposium

*Scientific Chair : Ahmet Burhan Ferhanoğlu
The Evolving Role of Venetoclax in the Era of Novel R/R CLL Therapies Michael Hallek (13:30 - 14:15)
22.05.2021
14:15 - 14:45

Break

22.05.2021
14:45 - 16:15
Hall A

Hodgkin Lymphoma

*Scientific Chair : Muhit Özcan , Bastian Von Tresckow
Firstline Treatment of HL Paul Bröckelmann (14:45 - 16:15)
Update on NLPHL Dennis Eichenauer (14:45 - 16:15)
Relapsed and Refractory HL: Innovative Therapies Bastian Von Tresckow (14:45 - 16:15)
22.05.2021
16:15 - 16:45

Break

22.05.2021
16:45 - 17:30
Hall A

Janssen Satellite Symposium

*Scientific Chair : Ahmet Muzaffer Demir
How Biology is Informing Treatment Decisions in Firstline CLL ? Fatih Demirkan (16:45 - 17:30)
Breakthrough CLL Disease Control in Relapsed & Refractory Settings: Long Term Ibrutinib Outcomes Önder Arslan (16:45 - 17:30)
22.05.2021
17:30 - 18:00

Break

22.05.2021
18:00 - 19:30
Hall A

Acute Lymphoblastic Leukemia

*Scientific Chair : Önder Arslan , Dieter Hoelzer
Immunotherapies in B-Lineage ALL Dieter Hoelzer (18:00 - 19:30)
Current Status and Future Prospects in T-ALL Nicolas Boissel (18:00 - 19:30)
Progress in Ph+/Ph-like ALL Oliver Ottmann (18:00 - 19:30)
22.05.2021
19:30 - 20:00

Break

22.05.2021
20:00 - 21:30
Hall A

Aggressive Lymphomas

*Scientific Chair : Ahmet Burhan Ferhanoğlu , Martin Dreyling
Primary CNS Lymphoma Andres Ferreri (20:00 - 21:30)
Mantle Cell Lymphoma Martin Dreyling (20:00 - 21:30)
CAR T-Cells in DLBCL Marion Subklewe (20:00 - 21:30)
22.05.2021
21:30 - 21:45

Break

22.05.2021
21:45 - 22:00
Hall A

Closing Remarks